This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Dr. Johnson's letter was referred to Dr. DeLong who offers the following reply:
To the Editor:
Of the 131 patients examined, 59 were male of whom 23 (39%) had ocular changes associated with long-term chlorpromazine therapy, and 72 were females of whom 26 (36%) had ocular changes. Of those examined, 106 were Caucasian, of whom 40 (38%) had ocular changes, and 25 were Negro, of whom nine (36%) had ocular changes. Of the latter group, 12 were males, of whom five had ocular changes and 13 were females of whom four had ocular changes. It can be readily seen that a little over one-third of the patients examined showed ocular changes associated with long-term chlorpromazine therapy whether they be male, female, Caucasian or Negro.
DeLong SL. LONG-TERM CHLORPROMAZINE THERAPY-Reply. Arch Ophthalmol. 1965;74(3):442–443. doi:10.1001/archopht.1965.00970040444035
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: